News
-
-
-
-
-
-
PRESS RELEASE
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
Bausch Health Companies Inc. presents positive data from Amiselimod clinical trials for ulcerative colitis treatment at global healthcare conferences. Rifaximin monotherapy data also showed promise for hepatic encephalopathy recurrence prevention -
-
PRESS RELEASE
Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
Bausch Health Canada expands UCERIS availability in Canadian public drug plans for ulcerative colitis treatment. UCERIS foam offers better tolerability and application compared to enema -
-
PRESS RELEASE
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
Bausch Health & Salix Pharmaceuticals to present Phase 2 trial data on Amiselimod for ulcerative colitis treatment at DDW 2024. Positive results announced in 2023
![Accesswire](/assets/images/accesswire-inline.png)
-
Eagle Plains Announces Conditional Approval of Warrant Expiry Extension
-
Goldflare Announces Changes in Leadership
-
Gina Corena & Associates Participates in 2024 Nevada Justice Association Annual Summer Gala This Weekend
-
Canada Jetlines Announces Loan
-
Pixalate Introduces EMEA Connected TV (CTV) Supply-Side Platform (SSP) Market Share Rankings: Magnite No. 1 With 43% Market Share in Q1 2024
![EQS Group](/assets/images/eqs-group.png)
-
EQS-Adhoc: VOLKSWAGEN AKTIENGESELLSCHAFT: Volkswagen AG resolves on investment by Volkswagen of initially 1 billion USD in Rivian Automotive, Inc., and intends to establish a joint venture
-
CompuGroup Medical strengthens market position in Northern Europe with the acquisition of Norwegian Pridok
-
EQS-Adhoc: CompuGroup Medical SE & Co. KGaA: CompuGroup Medical acquires Pridok AS
-
Molten Ventures Plc: HOL-Holding(s) in Company
-
Annual General Meeting 2024 of Meyer Burger approves all motions
![Les Echos](/assets/images/les-echos.png)
-
RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024
-
Schneider Electric announces the reference share price and the initial conversion/exchange ratio of its new bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2031 and the results of the repurchase of the OCEANEs
-
FREY signs new financing for €400m
-
Schneider Electric announces the success of its offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2031 for a nominal amount of €750 million
-
Cie du Bois Sauvage: Buy back of own shares – week from 17/06/2024 to 21/06/2024